UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Free prostate-specific antigen in serum is becoming more complex

Urology, 2002-06, Vol.59 (6), p.797-802

2002

Link zum Volltext

Verfügbarkeit prüfen

Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis

Urology (Ridgewood, N.J.), 2003-02, Vol.61 (2), p.274-276

2003

Link zum Volltext

Verfügbarkeit prüfen

Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood

Molecular cancer, 2010-07, Vol.9 (1), p.174-174, Article 174

2010

Link zum Volltext

Verfügbarkeit prüfen

Molecular PCA3 diagnostics on prostatic fluid

The Prostate, 2007-06, Vol.67 (8), p.881-887

2007

Link zum Volltext

Verfügbarkeit prüfen

Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer

The Keio Journal of Medicine, 2003, Vol.52(2), pp.86-91

2003

Link zum Volltext

Verfügbarkeit prüfen

Clinical utility of proPSA and “benign” PSA when percent free PSA is less than 15

Urology (Ridgewood, N.J.), 2004-12, Vol.64 (6), p.1160-1164

2004

Link zum Volltext

Verfügbarkeit prüfen

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

The Journal of urology, 2004-06, Vol.171 (6 Pt 1), p.2239

2004

Link zum Volltext

Verfügbarkeit prüfen

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

The Journal of urology, 2003-12, Vol.170 (6 Pt 1), p.2181

2003

Link zum Volltext

Verfügbarkeit prüfen

Proenzyme Forms of Prostate-Specific Antigen in Serum Improve the Detection of Prostate Cancer

Clinical chemistry (Baltimore, Md.), 2004-06, Vol.50 (6), p.1017-1025

2004

Link zum Volltext

Verfügbarkeit prüfen

Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results

The Prostate, 2008-08, Vol.68 (11), p.1215-1222

2008

Link zum Volltext

Verfügbarkeit prüfen

New nomenclature for the human tissue kallikrein gene family

Clinical chemistry (Baltimore, Md.), 2000-11, Vol.46 (11), p.1855-1858

2000

Link zum Volltext

Verfügbarkeit prüfen

Benign Prostate-specific Antigen (BPSA) in Serum Is Increased in Benign Prostate Disease

Clinical chemistry (Baltimore, Md.), 2003-02, Vol.49 (2), p.253-259

2003

Link zum Volltext

Verfügbarkeit prüfen

Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease

Rinsho byori. The Japanese journal of clinical pathology, 2004-03, Vol.52 (3), p.223

2004

Link zum Volltext

Verfügbarkeit prüfen

The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia

Clinical chemistry (Baltimore, Md.), 1998-10, Vol.44 (10), p.2115-2119

1998

Link zum Volltext

Verfügbarkeit prüfen

Are multiple markers the future of prostate cancer diagnostics?

Clinical Biochemistry, 2004-07, Vol.37 (7), p.519-528

2004

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml

The Journal of urology, 2003-09, Vol.170 (3), p.723

2003

Link zum Volltext

Verfügbarkeit prüfen

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue

Cancer research (Chicago, Ill.), 2000-02, Vol.60 (3), p.756-759

2000

Link zum Volltext

Verfügbarkeit prüfen

“BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

Urology (Ridgewood, N.J.), 2000, Vol.55 (1), p.41-45

2000

Link zum Volltext

Verfügbarkeit prüfen

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness

The Journal of urology, 2004-06, Vol.171 (6 Pt 1), p.2245

2004

Link zum Volltext

Verfügbarkeit prüfen

Human Kallikrein 2 (hK2) and Prostate-Specific Antigen (PSA): Two Closely Related, but Distinct, Kallikreins in the Prostate

Critical reviews in clinical laboratory sciences, 1998-01, Vol.35 (4), p.275-368

1998

Link zum Volltext

Verfügbarkeit prüfen

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

Urology (Ridgewood, N.J.), 1999-11, Vol.54 (5), p.839-845

1999

Link zum Volltext

Verfügbarkeit prüfen

Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when psa levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model

Urology (Ridgewood, N.J.), 1999-08, Vol.54 (2), p.220-224

1999

Link zum Volltext

Verfügbarkeit prüfen

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen

Urology (Ridgewood, N.J.), 2003-07, Vol.62 (1), p.177-181

2003

Link zum Volltext

Verfügbarkeit prüfen

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer

Urology, 2002, Vol.59 (1), p.2-8

2002

Link zum Volltext

Verfügbarkeit prüfen

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer

Urology (Ridgewood, N.J.), 2004-05, Vol.63 (5), p.905-910

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(86)

Sprache

Englisch
(86)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Life Sciences & Biomedicine
(69)
Humans
(65)
Male
(59)
Biological And Medical Sciences
(49)
Medical Sciences
(46)
Nephrology. Urinary Tract Diseases
(34)
Tumors Of The Urinary System
(33)
Urinary Tract. Prostate Gland
(33)
Urology & Nephrology
(33)
Prostate-Specific Antigen - Blood
(31)
Middle Aged
(27)
Aged
(25)
Prostatic Neoplasms - Diagnosis
(23)
Prostatic Neoplasms - Blood
(22)
Sensitivity And Specificity
(21)
Prostatic Neoplasms - Pathology
(20)
Prostate Cancer
(18)
Investigative Techniques, Diagnostic Techniques
(15)
Prostate-Specific Antigen
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Free prostate-specific antigen in serum is becoming more complex

Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis

Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood

Molecular PCA3 diagnostics on prostatic fluid

Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer

Clinical utility of proPSA and “benign” PSA when percent free PSA is less than 15

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

Proenzyme Forms of Prostate-Specific Antigen in Serum Improve the Detection of Prostate Cancer

Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results

New nomenclature for the human tissue kallikrein gene family

Benign Prostate-specific Antigen (BPSA) in Serum Is Increased in Benign Prostate Disease

Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease

The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia

Are multiple markers the future of prostate cancer diagnostics?

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue

“BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness

Human Kallikrein 2 (hK2) and Prostate-Specific Antigen (PSA): Two Closely Related, but Distinct, Kallikreins in the Prostate

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when psa levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer

Suchergebnisse filtern